Yenidoğanlarda Antifungal İlaç Kullanımı

Abstract

Invasive candidiasis is responsible for about 10% of nosocomial sepsis and it continues to be significant cause of serious morbidity and mortality in very low birth weight infants. Alhough the informations about the antifungal drugs which used for Candida species are increasing, studies and conclusions about the efficacy and safety are still insufficient. Most of the studies have focused on the pharmacokinetic and pharmacodynamic evaluations and obtained from adult patients. However, efectiveness of the therapy can not be same in newborns due to the different pathophysiology of neonatal candidiasis in newborn, the inferences can not be considered from adult studies. Until now, amphotericin B deoxycholate, fluconazole and micafungin seems to be effectivev therapy for the treatment of neonatal invasive candidiasis. Herein, the medical literature has been scanned and compiled with the latest information about the use of antifungal agents in newborn.